Kymera Therapeutics Presents Clinical Data from the Phase 1 Trial of IRAK4 Degrader, KT-474 (SAR444656), at the European Academy of Dermatology and Venereology Symposium

May 18, 2023 by Leave a Comment

Last Updated on May 18, 2023 by

[#item_full_content]

Spread the word

You must log in to post a comment.

We provide a balanced view on small cap biotech equities

Address : Santa Fe, New Mexico.

Generated by Feedzy

%d bloggers like this:

Reader Interactions